Another Look at Pyrroloiminoquinone Alkaloids—Perspectives on Their Therapeutic Potential from Known Structures and Semisynthetic Analogues
AbstractThis study began with the goal of identifying constituents from Zyzzya fuliginosa extracts that showed selectivity in our primary cytotoxicity screen against the PANC-1 tumor cell line. During the course of this project, which focused on six Z. fuliginosa samples collected from various regions of the Indo-Pacific, known compounds were obtained consisting of nine makaluvamine and three damirone analogues. Four new acetylated derivatives were also prepared. High-accuracy electrospray ionization mass spectrometry (HAESI-MS) m/z ions produced through MS2 runs were obtained and interpreted to provide a rapid way for dereplicating isomers containing a pyrrolo[4,3,2-de]quinoline core. In vitro human pancreas/duct epithelioid carcinoma (PANC-1) cell line IC50 data was obtained for 16 compounds and two therapeutic standards. These results along with data gleaned from the literature provided useful structure activity relationship conclusions. Three structural motifs proved to be important in maximizing potency against PANC-1: (i) conjugation within the core of the ABC-ring; (ii) the presence of a positive charge in the C-ring; and (iii) inclusion of a 4-ethyl phenol or 4-ethyl phenol acetate substituent off the B-ring. Two compounds, makaluvamine J (9) and 15-O-acetyl makaluvamine J (15), contained all three of these frameworks and exhibited the best potency with IC50 values of 54 nM and 81 nM, respectively. These two most potent analogs were then tested against the OVCAR-5 cell line and the presence of the acetyl group increased the potency 14-fold from that of 9 whose IC50 = 120 nM vs. that of 15 having IC50 = 8.6 nM. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 3061 KB)
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Lin, S.; McCauley, E.P.; Lorig-Roach, N.; Tenney, K.; Naphen, C.N.; Yang, A.-M.; Johnson, T.A.; Hernadez, T.; Rattan, R.; Valeriote, F.A.; Crews, P. Another Look at Pyrroloiminoquinone Alkaloids—Perspectives on Their Therapeutic Potential from Known Structures and Semisynthetic Analogues. Mar. Drugs 2017, 15, 98.
Lin S, McCauley EP, Lorig-Roach N, Tenney K, Naphen CN, Yang A-M, Johnson TA, Hernadez T, Rattan R, Valeriote FA, Crews P. Another Look at Pyrroloiminoquinone Alkaloids—Perspectives on Their Therapeutic Potential from Known Structures and Semisynthetic Analogues. Marine Drugs. 2017; 15(4):98.Chicago/Turabian Style
Lin, Sheng; McCauley, Erin P.; Lorig-Roach, Nicholas; Tenney, Karen; Naphen, Cassandra N.; Yang, Ai-Mei; Johnson, Tyler A.; Hernadez, Thalia; Rattan, Ramandeep; Valeriote, Frederick A.; Crews, Phillip. 2017. "Another Look at Pyrroloiminoquinone Alkaloids—Perspectives on Their Therapeutic Potential from Known Structures and Semisynthetic Analogues." Mar. Drugs 15, no. 4: 98.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.